Sildenafil - Raynaud's Phenomenon

You are here : Home > Formulary Search > Sildenafil - Raynaud's Phenomenon

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Transfer of prescribing to primary care only after specialist team initiation and supply of at least the first month of treatment.

Documentation

Shared Care

Sildenafil in Raynaud’s Phenomenon - BLUE information sheet - April 2021.pdf

Evidence Review

Sildenafil in Raynauds Phenomenon - Evidence review - December 2020.pdf

PAD Profile

ChemicalSubstance :

Sildenafil

Indication :

Raynaud's Phenomenon

Group Name :

Keywords :

digital ulceration, Raynaud's disease, Raynaud's syndrome, systemic sclerosis

Brand Names Include :

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Sildenafil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Raynaud's Phenomenon.

Committee Recommendations (1)

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee approves sildenafil (generic – off label use) for the treatment of Raynauds Phenomenon (RP) secondary to systemic sclerosis, in patients with or without digital ulceration.

Sildenafil will be given a BLUE (with information sheet) traffic light status.

Please see the BLUE information sheet (agreed in April 2021) below for further information.